New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 3, 2013
09:19 EDTAAPL, GMAN, FIO, ASNA, OMED, CELG, FTNT, NVS, UNIS, YUM, CHL, DIS, KKD, TSLA, LXRXOn The Fly: Pre-market Movers
HIGHER: Apple (AAPL), up 1% following upgrade at UBS, purchase of social-media analytics firm Topsy Labs, new report of expected but unconfirmed China Mobile (CHL) partnership... Tesla (TSLA), up 7% after German review found no manufacturer-related defects, stock named a Top Pick at Morgan Stanley... Ascena Retail (ASNA), up 4% after earnings report... OncoMed (OMED), up 82% after deal to jointly develop anti-CSC candidates with Celgene (CELG)... Unilife (UNIS), up 20% after announcing a clinical product supply agreement with Novartis (NVS)... Fortinet (FTNT), up 2.5% after upgraded at BofA Merrill Lynch... DOWN AFTER EARNINGS: Krispy Kreme (KKD), down 15%... Gordmans Stores (GMAN), down 6.5%. ALSO LOWER: Yum! Brands (YUM) down 2.8% after China sales update... Lexicon (LXRX), down 9.5% after Phase 2 study primary endpoint not statistically significant... Disney (DIS), down 1% following downgrade at B. Riley... Fusion-io (FIO), down 4% after downgraded at UBS.
News For AAPL;TSLA;KKD;DIS;CHL;YUM;UNIS;NVS;FTNT;CELG;OMED;ASNA;FIO;GMAN;LXRX From The Last 14 Days
Check below for free stories on AAPL;TSLA;KKD;DIS;CHL;YUM;UNIS;NVS;FTNT;CELG;OMED;ASNA;FIO;GMAN;LXRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>
April 4, 2014
12:14 EDTTSLATesla breaks nascent uptrend, levels to watch
Subscribe for More Information
10:45 EDTCELGMylan rises despite Meda rejecting takeover offer
Mylan (MYL) shares are higher this morning following a Financial Times report of its desire to buy Swedish rival Meda. Subsequent to the story being published, Meda confirmed it had been in talks with Mylan but rejected the company's takeover offer. WHAT'S NEW: The Financial Times reported that Mylan was considering buying Meda, a Swedish drugmaker, in a deal that would create a $23B+ pharmaceuticals business. Mylan reportedly hired advisers to put a deal together for Meda, and though the value of a deal was not noted, sources said Mylan was likely to pay a "significant" premium to Meda's market value, which was $4.5B at the end of trading on Thursday. Mylan's market value currently stands at $18.5B. A combination of the drugmakers would create a company with annual revenues of around $9B, the FT said, noting that would be half the size of generic drug rival Teva (TEVA). WHAT'S NOTABLE: Meda's board of directors confirmed that it was contacted by Mylan regarding a proposal to merge the companies, but the board decided to reject the proposal. Meda said all discussions between the company and Mylan have been terminated "without further actions." ANALYST REACTION: Citigroup upgraded Mylan to Buy from Neutral and raised its price target on the stock to $61 from $52 this morning. The firm cited potential operational and tax benefits from an acquisition of Meda, stating that in addition to expanding Mylan's geographic presence, the deal would increase its presence in specialty, OTC and branded generics. OTHER NEWS: Mylan sued Celgene (CELG) to block that company's efforts to keep generic versions of Revlimid and Thalomid off the market, Reuters reported. PRICE ACTION: Mylan shares are up $2.98, or 5.98%, to $52.84 in mid-morning trading.
09:45 EDTFTNTWells questions validity of low FireEye score in NSS Labs report
Subscribe for More Information
09:36 EDTAAPL, TSLAActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL TSLA MU GNK AMZN FB GILD MA NFLX
08:18 EDTAAPLApple June quarter results likely to miss expectations, says BMO Capital
Subscribe for More Information
06:49 EDTCELGMylan sues Celgene for blocking Thalomid, Revlimid generics, Reuters says
Subscribe for More Information
06:14 EDTAAPLApple acquires Novauris, terms not disclosed, Re/code reports
Apple has confirmed that it has acquired Novauris Technologies, a speech technology company, Re/code reports. Reference Link
April 3, 2014
16:00 EDTTSLA, AAPLOptions Update; April 3, 2014
Subscribe for More Information
14:59 EDTDISWalt Disney volatility low into “Captain America: The Winter Soldier”
Walt Disney April weekly call option implied volatility at 20, May is at 22, July is at 20; compared to its 26-week average of 23 according to Track Data, suggesting decreasing price movement into the release “Captain America: The Winter Soldier”.
09:37 EDTTSLA, AAPLActive equity options trading on open
Subscribe for More Information
09:30 EDTAAPLApple, Pfizer others create 'go slow' patent lobby group, Reuters says
Subscribe for More Information
09:14 EDTFIOOn The Fly: Pre-market Movers
Subscribe for More Information
08:06 EDTNVSApricus Biosciences granted national phase approval for Vitaros in Luxembourg
Apricus Biosciences (APRI) announced that the Ministry of Health of Luxembourg has granted national phase approval to Vitaros, Apricus' novel topical on-demand treatment for erectile dysfunction. The company has now received a total of nine national phase approvals for Vitaros®, including Luxembourg, Belgium, France, Germany, Ireland, Italy, the Netherlands, Sweden and the United Kingdom following its broad approval by European health authorities in June 2013. Apricus has an exclusive commercialization partnership in place with Hexal AG, an affiliate within the Sandoz Division of the Novartis (NVS), for the commercialization of Vitaros in several European countries, including Luxembourg.
07:47 EDTTSLATesla suing NJ over being 'unfairly targeted' by new rules, AP says
Subscribe for More Information
07:40 EDTAAPLApple bulls bet new products to prompt stock revival, Bloomberg says
Subscribe for More Information
06:28 EDTCELGAtopic dermatitis could bring upside to Regeneron, Celgene, says Citigroup
Citigroup believes Regeneron's (REGN) dupilumab and Celgene's (CELG) Otezla for atopic dermatitis are being overlooked by investors and could provide upside for both names. Citi believes both drugs have good efficacy but adds that dupilumab is more advanced. The firm has a Buy rating on both stocks.
06:26 EDTNVSNovartis placing temporary moratorium on all IIT funding in Japan
Subscribe for More Information
06:26 EDTNVSNovartis announces third-party internal review of IITs
06:25 EDTNVSNovartis appoints Dirk Koshce as head of Novartis Pharmaceuticals
Subscribe for More Information
05:31 EDTNVSNovartis says data on 19 investigational compounds to be presented
Novartis announced that early stage data on 19 investigational compounds in its oncology pipeline will be presented at the annual meeting of the American Association of Cancer Research. Among the data being presented are single agent and combination studies with key investigational compounds in the Novartis Oncology breast cancer development program, including an early phase study of the CDK4/6 inhibitor LEE011 and PI3K inhibitors BKM120 and BYL719. LEE011 and BKM120 are currently in Phase III and BYL719 is in Phase I trials for the treatment of advanced breast cancer.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use